Profile of serum testosterone levels after application of testosterone ointment (glowmin) and its clinical efficacy in late-onset hypogonadism patients

Journal of Sexual Medicine

Volumn 5, Issue 7, 2008, Pages 1727-1736

  Amano, Toshiyasu ^a   Imao, Tetsuya ^a   Takemae, Katsurou ^a   Iwamoto, Teruaki ^b,c   Yamakawa, Katsunori ^c   Baba, Katsuyuki ^c   Nakanome, Mariko ^c   Sugimori, Hiroki ^c   Tanaka, Toshiaki ^c   Yoshida, Katsumi ^c   Katabami, Takuyuki ^c   Tanaka, Masami ^c  

^a NAGANO RED CROSS HOSPITAL   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Low onset hypogonadism; Serum testosterone level; Testosterone ointment

Indexed keywords

GLOWMIN; TESTOSTERONE;

ADULT; AGING; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICTURITION DISORDER; OINTMENT; PENIS ERECTION; PRIORITY JOURNAL; QUESTIONNAIRE; SCROTUM; SEBORRHEA; SENSORY DYSFUNCTION; SHORT FORM 36; SINGLE DRUG DOSE; TESTOSTERONE BLOOD LEVEL; VOLUNTEER;

EID: 47949107646     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00689.x     Document Type: Article

References (35)

1. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FCW. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005; 8: 56-8.
2. Lunenfeld B, Saad F, Hoesl CE. ISA, ISSAM and EAU recommendation for the investigation, treatment and monitoring of late-onset hypogonadism in males: Scientific background and rationale. Aging Male 2005; 8: 59-74.
3. Amano T, Kobori Y, Matsushita T, Takemae K. The role of Chinese herbal medicine in the treatment of partial androgen deficiency I aged male. Jpn J Impotence Res 2003; 18: 307-11.
4. Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord 1998; 48: 157-61.
5. Shamioui R, Ghanem H, Fahmy I, El-Meleigy A, Ashoor S, Elnashaar A, Kamei I. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: A pilot study. J Sex Med 2005; 2: 559-64.
6. Aversa A, Isidori AM, Greco EA, Giannetta E, Gianfrilli D, Spera E, Fabbri A. Hormonal supplementation and erectile dysfunction. Eur Urol 2004; 45: 535-8.
7. Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new "aging males' symptoms" rating scale. Aging Male 1999; 2: 105-14.
8. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-26.
9. Fukuhara S, Ware JE, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 healthy survey. J Clin Epidemiol 1998; 51: 1045-53.
10. Iwamoto T, Baba K. Diagnosis. In: Japanese Urological Association and Japanese Men's Health Association, eds. Guideline for LOH symptoms. Tokyo, Japan: Jiho Co.; 2007: 51-8.
11. Lazarou S, Reyes-Vallejo L, Morgentaler A. Wide variability in laboratory reference values for serum testosterone. J Sex Med 2006; 3: 1085-9.
12. Rosner W, Auchus RJ, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: An endocrine society position statement. J Clin Endocrinol Metab 2007; 92: 405-13.
13. Iwamoto T, Yanase T, Koh E, Horie H, Baba K, Namiki M, Nawata H. Reference ranges of serum total and free testosterone in Japanese male adults. Nippon Hinyokika Gakkai Zasshi 2004; 95: 751-60.
14. Crawford ED, Barqawi AB, O'donnel C, Morgentaler A. The association of time of day and serum testosterone concentration in large screening population. BJU Int 2007; 100: 509-13.
15. Tsujimura A, Matsumiya K, Takao T, Miyagawa Y, Takada S, Koga M, Iwasa A, Takeyama M, Okuyama A. Treatment with human chorionic gonadotropin for PADAM: A preliminary report. Aging Male 2005; 8: 175-9.
16. Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med 2001; 110: 563-72.
17. Morales A, Tenover JL. Androgen deficiency in the aging male: When, who, and how to investigate and treat. Urol Clin North Am 2002; 29: 975-82.
18. Tenover JL. Testosterone replacement therapy in older adult men. Int J Androl 1999; 22: 300-6.
19. Comhaire FH. Andropause: Hormone replacement therapy in the aging male. Eur Urol 2000; 38: 655-62.
20. Amano T. Androgen replacement therapy up-to-date ∼current status in Japan and abroad∼. Gender Sex Special Med (Jpn) 2006; 3: 65-70.
21. Kohn FM, Schill WB. A new oral testosterone undecanoate formulation. World J Urol 2003; 21: 311-5.
22. Juul A, Skakkebaek NE. Androgens and the aging. Hum Reprod Update 2002; 7: 423-33.
23. An NM, Kim DD, Shin YH, Lee CH. Development of novel soft hydrogel for the transdermal delivery of testosterone. Drug Dev Ind Pharm 2003; 29: 99-105.
24. Mazer N, Bell D, Wu J, Fisher J, Cosgrove M, Eilers B. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. J Sex Med 2005; 2: 213-26.
25. Amano T, Takemae K, Baba K, Nakazawa R, Nakanome M, Iwamoto T, Tanaka M, Yoshida K, Sugimori H, Tanaka T, Katabami T. Circadian rhythm and pharmacokinetic profiles of free testosterone after application of testosterone ointment in healthy men. Jpn J Impotence Res 2005; 20: 13-8.
26. Baba K, Nakazawa R, Nakanome M, Iwamoto T, Amano T, Tanaka T, Sugimori H, Yoshida K, Tanaka M, Katabami T. The effects of transdermal testosterone for hypogonadal men. Jpn J Impotence Res 2005; 20: 19-24.
27. Amano T, Imao T, Takemae K, Iwamoto T, Baba K, Yamakawa K, Nakazawa R, Yoshida K, Sugimori H, Tanaka T, Katabami T, Tanaka M. The efficacy of testosterone ointment (Glowmin) treatment for late-onset-hypogonadism (LOH) patients according to LOH severity. Hinyokika Kiyo 2007; 53: 25-9.
28. Miwa Y, Kaneda T, Yokoyama O. Correlation between the aging male's symptoms scale and sex steroids, gonadotropins, dehydroepiandrosterone sulfate, and growth hormone levels in ambulatory men. J Sex Med 2006; 3: 723-6.
29. 14C cortisol in man. J Invest Dermatol 1967; 48: 181-3.
30. Mazer N, Fisher D, Fisher J, Cosgrove M, Bell D, Eilers B. Transfer of transdermally applied testosterone to clothing: A comparison of a testosterone patch versus a testosterone gel. J Sex Med 2005; 2: 227-34.
31. Kirby R, Gould D. Testosterone replacement therapy in hypogonadal men and prostate cancer risk. BJU Int 2005; 96: 471-2.
32. El-Sakka AI, Hassoba HM, Elbakry AM, Hassan HA. Prostate specific antigen in patients with hypogonadism: Effect of testosterone replacement. J Sex Med 2005; 2: 235-40.
33. Rhoden EL, Morgentaler A. Risk of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482-92.
34. Gaylis FD, Lin DW, Ignatoff JM, Amling CL, Tutrone R, Cosgrove DJ. Prostate cancer in men using testosterone supplementation. J Urol 2005; 174: 534-8.
35. Morgentaler A. Testosterone and prostate cancer: A historical perspective on a modern myth. Eur Urol 2006; 50: 935-9.